Patients with which condition may require more injections for treatment of CNV in neovascular AMD?

Patients with an epiretinal membrane may require more injections for the treatment of choroidal neovascularization (CNV) in neovascular age-related macular degeneration (AMD) due to the impact of the membrane on visual function and retinal structure. An epiretinal membrane is a thin layer of fibrous tissue that can form on the surface of the retina, potentially complicating the course of disease and treatment in patients with AMD. This condition can exacerbate visual distortion and may contribute to a less effective response to treatment, leading practitioners to administer additional injections of anti-VEGF (vascular endothelial growth factor) agents to manage the CNV and improve visual outcomes.

In contrast, cataracts, while they can affect vision, do not directly influence the management of CNV in AMD. Macular degeneration itself is the condition being treated, and its severity dictates treatment rather than being a factor that necessitates more injections. Diabetic retinopathy, although it can also involve CNV, presents its unique treatment challenges that differ from those encountered in AMD and may not inherently require more injections for managing CNV specifically associated with AMD. Hence, the presence of an epiretinal membrane is a significant factor that may lead to increased treatment needs in the context